Cardio Diagnostics Holdings Schedules Investor Conference Call to Discuss Precision Cardiovascular Medicine Progress

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announced it will host an investor conference call on Feb. 19, 2026, at 3 p.m. Central Time to provide an overview of its precision molecular approach to cardiovascular disease prevention and early detection. The call will include updates on the company commercially available tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), as well as discussion of recent clinical data, reimbursement progress and strategic growth initiatives. This announcement matters because it represents a significant opportunity for investors and stakeholders to gain insights into the company's progress in making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise through artificial intelligence-powered technology.

The company's approach leverages a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine, which forms the foundation of their clinical tests. This technology represents an important advancement in cardiovascular medicine, as traditional risk assessment methods often fail to identify individuals at risk until symptoms appear. By combining genetic and epigenetic data through AI analysis, Cardio Diagnostics aims to provide earlier and more accurate detection of cardiovascular disease risk, potentially enabling preventive interventions before serious health consequences occur. The investor call will provide crucial information about how this technology is being implemented in clinical practice and its commercial trajectory.

Cardio Diagnostics' announcement is particularly important given the global burden of cardiovascular disease, which remains the leading cause of death worldwide according to the World Health Organization. The company's precision medicine approach addresses a critical need in healthcare by moving beyond one-size-fits-all prevention strategies toward personalized risk assessment. The upcoming investor conference call will offer insights into how the company is translating its technological innovations into practical clinical applications that could potentially transform cardiovascular care. For more information about the company's technology and approach, visit https://cdio.ai/.

The implications of this announcement extend beyond investor relations to the broader healthcare landscape. As precision medicine continues to gain traction across medical specialties, Cardio Diagnostics' progress in cardiovascular disease represents an important case study in how AI and molecular diagnostics can be integrated to improve patient outcomes. The discussion of reimbursement progress during the call will be particularly significant, as insurance coverage is a critical factor determining whether innovative diagnostic tests become widely accessible to patients. Strategic growth initiatives to be discussed may include expansion plans, partnerships, or new product developments that could further establish the company's position in the precision cardiovascular medicine market.

This investor conference call represents an important milestone for Cardio Diagnostics as it seeks to demonstrate the clinical and commercial viability of its precision cardiovascular medicine platform. The timing of the call in early 2026 suggests the company may be preparing to share significant developments that have occurred since its last major update. For those interested in the intersection of artificial intelligence, molecular diagnostics, and cardiovascular health, this event provides a valuable opportunity to understand how one company is working to address one of medicine's most persistent challenges through innovative technology. The full press release containing additional details about the conference call can be accessed at https://ibn.fm/3xwFk.